Role of cyclin e1 overexpression in triple negative breastcancer

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking the expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2). Although It has basaloid structure, it is %20-30 different from basal like breast cancer. Compared to other subtypes, which can be treated with targeted therapies, chemotherapy is the major regimen used to treat TNBCs. There is no viable target and therfore personalized treatment program specifically for TNBC subtype. CCNE1 along with its catalytic subunit Cyclin-dependent kinase-2 (CDK2), plays a critical role in cell cycle regulation, DNA replication, chromosome segregation, and G1-S transition. In this study, we showed that CCNE1 gene can be a potential treatment target and disease prognosis biomarker, with statistically high expression at mRNA and protein levels in TNBC compared to other breast cancer subtypes.